Bio-techne CORP Form 4 insider transactions

John L Higgins, a Director of BIO-TECHNE Corp, reported multiple transactions in common stock on September 28, 2026.

Robert Baumgartner V, a Director of BIO-TECHNE Corp, reported multiple transactions in common stock on September 22, 2026.

Kim Kelderman, Chief Executive Officer and a Director of BIO-TECHNE Corp, reported multiple transactions in common stock on August 17, 2026.

James Hippel, CFO of BIO-TECHNE Corp, reported multiple transactions in common stock on August 17, 2026.

Amy E. Herr, a Director of BIO-TECHNE Corp, received 1,381 shares of common stock on August 17, 2026.

William Geist, PRESIDENT, PROTEIN SCIENCES of BIO-TECHNE Corp, reported multiple transactions in common stock on August 17, 2026.

Steven C. Crouse, President - Diag & Spatial Bi of BIO-TECHNE Corp, reported multiple transactions in common stock on August 17, 2026.

Kim Kelderman, Chief Executive Officer and a Director of BIO-TECHNE Corp, reported multiple transactions in common stock on August 15, 2026.

James Hippel, CFO of BIO-TECHNE Corp, reported multiple transactions in common stock on August 15, 2026.

William Geist, PRESIDENT, PROTEIN SCIENCES of BIO-TECHNE Corp, reported multiple transactions in common stock on August 15, 2026.

Shane Bohnen, SVP - General Counsel of BIO-TECHNE Corp, reported multiple transactions in common stock on August 15, 2026.

James Hippel, CFO of BIO-TECHNE Corp, reported multiple transactions in common stock on July 29, 2026.

Kim Kelderman, Chief Executive Officer and a Director of BIO-TECHNE Corp, reported multiple transactions in common stock on July 28, 2026.

Shane Bohnen, SVP - General Counsel of BIO-TECHNE Corp, reported multiple transactions in common stock on July 23, 2026.

Steven C. Crouse, President of Diagnostics & Spatial Biology at Bio-Techne, reported the vesting and sale of common stock.

Bio-Techne Corp. Director Amy E. Herr reported a sale of 6,636 shares of common stock on May 8, 2026, for approximately $48.28 per share.

CFO James Hippel exercised 62,000 stock options and subsequently withheld 56,955 shares to cover tax obligations.

SVP and General Counsel Shane Bohnen exercised 8,400 stock options and subsequently withheld shares for tax obligations.

CEO Kim Kelderman exercised 26,692 stock options and retained a portion of the resulting shares.

CEO Kim Kelderman exercised 11,344 stock options and retained the resulting shares after a tax-related disposition.

CFO James Hippel exercised 62,000 stock options and sold a portion to cover tax obligations, resulting in a net increase in direct share ownership.

CEO Kim Kelderman exercised 36,500 stock options and withheld 32,088 shares to cover tax obligations.

Shane Bohnen, SVP - General Counsel of Bio-Techne Corp, reported significant stock transactions including the acquisition of 2,259 restricted stock units and the disposal of 740 shares.

Steven C. Crouse, President of Diagnostics & Spatial Biology at Bio-Techne, reported the acquisition of new performance restricted stock units, restricted stock units, and stock options.

Amy E. Herr, a Director at Bio-Techne Corp, reported the sale of 1,976 shares of common stock for approximately $59.11 per share.

BIO-TECHNE Director Amy E. Herr disclosed routine transactions involving common stock and derivative securities, including RSU vesting and tax-related dispositions, executed under a 10b5-1 plan.

Matthew McManus, President of Diagnostics & Spatial Biology at BIO-TECHNE, reported the exercise of restricted stock units and a subsequent sale of shares to cover tax obligations.

BIO-TECHNE Corp's CEO, Kim Kelderman, reported the disposition of 2,303 common shares at $62.57 each to cover tax withholding obligations.

BIO-TECHNE's CFO, James Hippel, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Bio-Techne's President of Protein Sciences, William Geist, reported the vesting of restricted stock units and a subsequent sale of shares for tax purposes.